More time is needed to gauge whether the US Food and Drug Administration's rare pediatric disease priority review voucher program has actually encouraged the development of new treatments, the Government Accountability Office believes. The FDA, however, isn't interested in giving the incentive program any more time to try to prove itself.
"FDA officials expressed concern about the pediatric voucher program, and do not support its continuation after its current authorization expires in Oct. 1, 2016," GAO said in a March 2...